1、教育经历
2015.01-2019.12 德州大学艾尔帕索分校，生命科学系，获得博士学位
2012.08-2014.05 罗斯福大学，生物技术专业，获得硕士学位
2006.09-2010.06 中国药科大学，药剂学专业，获得学士学位
2、工作经历
(1) 2020/07-至今， 中国药科大学， 药学院， 讲师
(1) 胶质母细胞瘤病理机制
(2) 胶质母细胞瘤药物新靶点探索
1、科研项目
(1) 中国药科大学, 中央高校基本科研业务费, 2632021PY05, IMP2经由ECM/Integrin通路调控胶质母细胞 瘤异质性表达的研究, 2021-01 至 今, 8.00万元, 在研, 主持
1.Xing, M.; Wang, X.; Kirken, R. A.; He, L.; Zhang, J. Y., Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment. International journal of molecular sciences 2021, 22 (11). IF:6.208
2.Ma, P.; Xing, M .*; Han, L.; Gan, S.; Ma, J.; Wu, F.; Huang, Y.; Chen, Y.; Tian, W.; An, C.; Sun, L. High PDL1 expression drives glycolysis via an Akt/mTOR/HIF1alpha axis in acute myeloid leukemia. Oncology reports 2020, 43 (3), 999-1009. IF:3.906
3.Xing, M.; Li, P.; Wang, X.; Li, J.; Shi, J.; Qin, J.; Zhang, X.; Ma, Y.; Francia, G.; Zhang, J. Y., Overexpression of p62/IMP2 can Promote Cell Migration in Hepatocellular Carcinoma via Activation of the Wnt/beta-Catenin Pathway. Cancers 2019, 12 (1). IF :6.162
4.Dai, X.; Theobard, R.; Cheng, H.; Xing, M.; Zhang, J., Fusion genes: A promising tool combating against cancer. Biochimica et biophysica acta. Reviews on cancer 2018, 1869 (2), 149-160. IF:8.220
5.Dai, L.; Li, J.; Xing, M.; Sanchez, T.; Casiano, C.; Zhang, J.Y. Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With Prostate Cancer. Prostate 2016, 76(15), 1375-1386. IF:3.820
6.Li, J.; Dai, L.; Lei, N.; Xing, M.; Li, P.; Luo, C.; Casiano, C.; Zhang, J.Y. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer. Oncotarget 2016, 7(28), 43546-43556. IF:5.168
7.Du, J.; Guo, Y.; Bao, Y.; Xing, M.; Mahmoud, A. M.; Che, Z.; Chen, Z.; Yang, W., Anticancer activities of sulindac in prostate cancer cells associated with c-Jun NH2-terminal kinase 1/beta-catenin signaling. Oncology letters 2014, 8 (1), 313-316.
IF:1.554
